The Blindsight device aims to restore vision, even for those who have been blind since birth. Credit: H_Ko / Shutterstock.

Neurotechnology company Neuralink has secured a breakthrough device designation from the US Food and Drug Administration (FDA) for its Blindsight device.

This advanced technology promises to restore vision, even to those who have been blind since birth, provided their visual cortex remains intact.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Blindsight device is designed to process and transmit neural signals, potentially allowing individuals without eyes or an optic nerve to perceive visual information.

The visual resolution will initially be basic, similar to early video game graphics, but there is potential for significant improvements, including the ability to see in different wavelengths such as infrared and ultraviolet.

Neuralink’s technology includes a chip that could interface with digital devices such as computers or phones, reported Reuters.

See Also:

The company is concurrently conducting trials on an implant that could enable paralysed patients to operate digital devices through thought alone, offering new hope for individuals with spinal cord injuries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s clinical trial, aiming to enrol three patients, is anticipated to span several years, as detailed in the US Government’s clinical trials database.

Neuralink received FDA approval for its first human study in May 2023. The company had expressed on Twitter that this approval marks a crucial initial step towards utilising its technology to aid numerous individuals.

Last month, Neuralink’s founder Elon Musk announced the successful implantation of the brain-chip device in a second patient.

Musk established Neuralink to address various health issues, with blindness and paralysis being the primary targets.